ReviewBasic research in cardiology2025
Exercise, cancer, and the cardiovascular system: clinical effects and mechanistic insights.
Review in Basic research in cardiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06672120 (Exercise in Regional Breast Cancer With Neoadjuvant Anthracycline- Based Chemotherapy and Immunotherapy With Checkpoint-Inhibition), which is not on this map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Exercise in Regional Breast Cancer With Neoadjuvant Anthracycline- Based Chemotherapy and Immunotherapy With Checkpoint-Inhibition
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.
- Cardiovascular mortality in people with cancer compared to the general population: A systematic review and meta-analysis.Cancer medicine · 2024Pooled it
- The Current Role of Physiotherapy in Systemic Light-Chain (AL) Amyloidosis and Multiple Myeloma.Life (Basel, Switzerland) · 2026Review
- Exercise Craving: A Scale Development Study.Health science reports · 2026Article
- A Scoping Review of Exercise Oncology in the Primary Brain Tumor Patient-Caregiver Dyad.Current oncology (Toronto, Ont.) · 2026Article
- Exercise in regional breast cancer with neoadjuvant anthracycline-based chemotherapy with immune checkpoint-inhibition: study protocol for a prospective randomised controlled trial.Frontiers in oncology · 2026Article
- Cancer and Cardiovascular Disease: Shared Risk Factors, Mechanisms, and Clinical Implications: JACC: CardioOncology State-of-the-Art Review.JACC. CardioOncology · 2025Review
- One-year longitudinal association between changes in aortic regional morphology and muscle mass in cancer.Scientific reports · 2025Article
- Exercise therapy: an effective approach to mitigate the risk of cancer metastasis.World journal of surgical oncology · 2025Review
- Cardiopulmonary Functional Profiles in Cancer Therapy-Related Cardiac Dysfunction Among Patients with Non-Hodgkin Lymphoma.Diagnostics (Basel, Switzerland) · 2025Article
- Effects of sex and obesity on immune checkpoint inhibition-related cardiac systolic dysfunction in aged mice.Basic research in cardiology · 2025Article
- Cardioprotection of voluntary exercise against breast cancer-induced cardiac injury via STAT3.Basic research in cardiology · 2025Article
- Association between exercise and clinical outcomes in patients treated with immunotherapy for solid tumors.Frontiers in immunology · 2025Article
- An interdisciplinary approach to ensure adherence to exercise and potentially reduce adverse cardiac events in cancer patients: primers in cardio-oncology.Frontiers in oncology · 2025Article
- Aerobic exercise-induced lactate production: a novel opportunity for remodeling the tumor microenvironment.Frontiers in genetics · 2025Review
- Relevance of Cardiovascular Exercise in Cancer and Cancer Therapy-Related Cardiac Dysfunction.Current heart failure reports · 2024Review
- Exercise During Chemotherapy Treatment as an Adjuvant Programme in Patients With Lymphoma (EDONOLA): Study Protocol for a Randomised Controlled Trial.Cancer control : journal of the Moffitt Cancer CenterArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiovascular diseases and cancer are the leading causes of death in the Western world and share common risk factors. Reduced cardiorespiratory fitness (CRF) is a major determinant of cardiovascular morbidity and cancer survival. In this review we discuss cancer- induced disturbances of parenchymal, cellular, and mitochondrial function, which limit CRF and may be antagonized and attenuated through exercise training. We show the impact of CRF on cancer survival and its attenuating effects on cardiotoxicity of cancer-related treatment. Tailored exercise programs are not yet available for each tumor entity as several trials were performed in heterogeneous populations without adequate cardiopulmonary exercise testing (CPET) prior to exercise prescription and with a wide variation of exercise modalities. There is emerging evidence that exercise may be a crucial pillar in cancer treatment and a tool to mitigate cardiotoxic treatment effects. We discuss modalities of aerobic exercise and resistance training and their potential to improve CRF in cancer patients and provide an example of a periodization model for exercise training in cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.